

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

NCT07043322

Status	RECRUITING
Phase	Phase 2
Sponsor	Tanta University
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (5)

- Age between 18-38 years
- Body mass index (calculated as weight in kilograms divided by the square of height in meters) ≤ 30 kg/m².
- A long luteal protocol is used for ovarian stimulation.
- Day 2 FSH ≤ 10 mIU/L and E2 ≤ 50 pg/ml
- High risk of OHSS, defined as having more than 20 follicles ≥ 12 mm in diameter and/or E2 levels ≥ 3000 pg/ml when the size of the leading follicle is ≥ 15 mm

Exclusion (2)

- The presence of chronic medical diseases, including liver cell failure, renal failure, uncontrolled hypertension, uncontrolled diabetes mellitus, or class 3 or 4 function heart disease in the New York heart association classification.
- Allergy to Cabergoline.

Locations (1 total)

Mostafa Bahaa, Damietta, New Damietta, Egypt